p16 hypermethylation: A biomarker for increased esophageal cancer susceptibility in high incidence region of North East India

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 1627-1642

  Das, Mandakini ^a   Saikia, Bhaskar Jyoti ^a   Sharma, Santanu Kumar ^a   Sekhon, Gaganpreet Singh ^a   Mahanta, Jagadish ^a   Phukan, Rup Kumar ^a  

^a REGIONAL MEDICAL RESEARCH CENTRE   (India)

Author keywords

Biomarker; Esophageal cancer; Methylation; North East India; p16 gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INCIDENCE; INDIA; MALE; MIDDLE AGED; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84930923449     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2762-7     Document Type: Article

References (39)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer 2012. http://globocan.iarc.fr. Accessed 11 Jul 2014.
2. NCRP. National cancer registry programme (NCRP) three year report of population based cancer registries: 2009–2011.
3. Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer. 2001;85(5):661–7. doi:10.1054/bjoc.2001.1920.
4. Phukan RK, Chetia CK, Ali MS, Mahanta J. Role of dietary habits in the development of esophageal cancer in Assam, the north-eastern region of India. Nutr Cancer. 2001;39(2):204–9. doi:10.1207/S15327914nc392_7.
5. Phukan RK, Zomawia E, Narain K, Hazarika NC, Mahanta J. Tobacco use and stomach cancer in Mizoram, India. Cancer Epidemiol Biomarkers Prev. 2005;14:1892–6. doi:10.1158/1055-9965.EPI-05-0074.
6. Talukdar FR, Ghosh SK, Laskar RS, Mondal R. Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India. PLoS One. 2013;8(4):e60996. doi:10.1371/journal.pone.0060996.
7. Adams L, Roth MJ, Abnet CC, Dawsey SP, Qiao YL, Wang GQ, et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev Res (Phila). 2008;1(5):357–61. doi:10.1158/1940-6207.CAPR-08-0061.
8. Zhang XM, Guo MZ. The value of epigenetic markers in esophageal cancer. Front Med China. 2010;4(4):378–84. doi:10.1007/s11684-010-0230-3.
9. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, et al. Role of epigenetic alterations in the pathogenesis of Barrett’s esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol. 2012;5(5):382–96.
10. Chik F, Szyf M, Rabbani SA. Role of epigenetics in cancer initiation and progression. Adv Exp Med Biol. 2011;720:91–104. doi:10.1007/978-1-4614-0254-1_8.
11. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ. Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer. Chin Med J. 2006;119(17):1469–72.
12. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers. 2013;5(2):676–713. doi:10.3390/cancers5020676.
13. Zhao SL, Zhu ST, Hao X, Li P, Zhang ST. Effects of DNA methyltransferase 1 inhibition on esophageal squamous cell carcinoma. Dis Esophagus. 2011;24(8):601–10. doi:10.1111/j.1442-2050.2011.01199.x.
14. Luczak MW, Roszak A, Pawlik P, Kedzia H, Kedzia W, Malkowska-Walczak B, et al. Transcriptional analysis of CXCR4, DNMT3A, DNMT3B and DNMT1 gene expression in primary advanced uterine cervical carcinoma. Int J Oncol. 2012;40(3):860–6. doi:10.3892/ijo.2011.1183.
15. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR. Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res. 2008;6(8):1365–74. doi:10.1158/1541-7786.MCR-08-0040.
16. Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics. 2011;6(3):307–16.
17. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol. 2005;26(6):1493–500.
18. Wu J, Liang B, He J, Zhang H, Wang Z. Study on detection of aberrant promoter hypermethylation of p16 and DAP kinase in serum DNA from patients with non-small cell lung cancer. Zhong Fei Ai Za Zhi. 2002;5(3):188–90. doi:10.3779/j.issn. 1009-3419.2002.03.09.
19. Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, et al. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol. 2003;16(9):944–50. doi:10.1097/01.MP.0000085760.74313.DD.
20. Ito S, Ohga T, Saeki H, Watanabe M, Kakeji Y, Morita M, et al. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma. Anticancer Res. 2007;27(5A):3345–53.
21. Roth MJ, Abnet CC, Hu N, Wang QH, Wei WQ, Green L, et al. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep. 2006;15(6):1591–7.
22. Sibin MK, Bhat DI, Lavanya C, Manoj MJ, Aakershita S, Chetan GK. CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients. Tumour Biol. 2014;35(2):1467–72. doi:10.1007/s13277-013-1201-5.
23. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res. 2004;10(18 Pt 1):6119–25. doi:10.1158/1078-0432.CCR-04-0652.
24. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 2007;80(20):1873–81. doi:10.1016/j.lfs.2007.02.026.
25. Wang CC, Mao WM, Ling ZQ. DNA methylation status of RARbeta2 and p16(INK4alpha) in peripheral blood and tumor tissue in patients with esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2012;34(6):441–5. doi:10.3760/cma.j.issn.0253-3766.2012.06.009.
26. Wang X, Zhu YB, Cui HP, Yu TT. Aberrant promoter methylation of p15 and p16 genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis. Tumour Biol. 2014. doi:10.1007/s13277-014-2054-2.
27. do Nascimento Borges B, Burbano RM, Harada ML. Analysis of the methylation patterns of the p16 INK4A, p15 INK4B, and APC genes in gastric adenocarcinoma patients from a Brazilian population. Tumour Biol. 2013;34(4):2127–33. doi:10.1007/s13277-013-0742-y.
28. Bhagat R, Kumar SS, Vaderhobli S, Premalata CS, Pallavi VR, Ramesh G, et al. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma. Tumour Biol. 2014. doi:10.1007/s13277-014-2136-1.
29. Yang W, Wang X, Li X, Wang M, Chen X, Wu X, et al. The specific methylation characteristics of cancer related genes in Chinese colorectal cancer patients. Tumour Biol. 2014. doi:10.1007/s13277-014-2100-0.
30. Zhang JC, Gao B, Yu ZT, Liu XB, Lu J, Xie F, et al. Promoter hypermethylation of p14 (ARF), RB, and INK4 gene family in hepatocellular carcinoma with hepatitis B virus infection. Tumour Biol. 2014;35(3):2795–802. doi:10.1007/s13277-013-1372-0.
31. Yi JM, Dhir M, Guzzetta AA, Iacobuzio-Donahue CA, Heo K, Yang KM, et al. DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol. 2012;33(2):363–72. doi:10.1007/s13277-011-0302-2.
32. Wang J, Sasco AJ, Fu C, Xue H, Guo G, Hua Z, et al. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2008;17(1):118–25. doi:10.1158/1055-9965.EPI-07-0733.
33. NCRP. National cancer registry programme (NCRP) three year report of population based cancer registries: 2006–2008.
34. Xu R, Wang F, Wu L, Wang J, Lu C. A systematic review of hypermethylation of p16 gene in esophageal cancer. Cancer Biomark. 2013;13(4):215–26. doi:10.3233/CBM-130355.
35. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest. 2010;120(2):521–32. doi:10.1172/JCI40706.
36. Zhao P, Lin F, Li Z, Lin B, Lin J, Luo R. Folate intake, methylenetetrahydrofolate reductase polymorphisms, and risk of esophageal cancer. Asian Pac J Cancer Prev. 2011;12(8):2019–23.
37. Aune D, Deneo-Pellegrini H, Ronco AL, Boffetta P, Acosta G, Mendilaharsu M, et al. Dietary folate intake and the risk of 11 types of cancer: a case–control study in Uruguay. Ann Oncol. 2011;22(2):444–51. doi:10.1093/annonc/mdq356.
38. Stidley CA, Picchi MA, Leng S, Willink R, Crowell RE, Flores KG, et al. Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res. 2010;70(2):568–74. doi:10.1158/0008-5472.CAN-09-3410.
39. Barrera LN, Cassidy A, Johnson IT, Bao Y, Belshaw NJ. Epigenetic and antioxidant effects of dietary isothiocyanates and selenium: potential implications for cancer chemoprevention. Proc Nutr Soc. 2012;71(2):237–45. doi:10.1017/S002966511200016X.